DNA-based Antipsoriatic Therapy Development Services
DNA-based therapies represent a promising avenue, utilizing genetic approaches to target the underlying mechanisms of psoriasis. At Ace Therapeutics, we specialize in providing preclinical services focused on the development of DNA-based therapies tailored to address the unique challenges associated with psoriasis.
Overview of Psoriasis and DNA-based Therapies
DNA-based therapies offer a potential approach by directly targeting the genetic factors that contribute to psoriasis. Techniques such as gene editing, gene silencing, and the use of plasmid DNA (pDNA) allow for precise modulation of gene expression. For instance, liposomal spherical nucleic acids (L-SNAs) have been designed to deliver antisense oligonucleotides that specifically target the IL-17 receptor, a key player in the inflammatory pathway of psoriasis. This targeted approach not only reduces the severity of inflammatory responses, but also minimizes potential off-target effects commonly associated with traditional therapies.
Fig. 1 Topical L-SNA treatment of psoriasis. (Korkmaz E, et al., 2020)
Comprehensive DNA-based Antipsoriatic Therapy Development Services
Ace Therapeutics provides a comprehensive suite of services tailored to the development of DNA-based therapies for psoriasis. Our expertise encompasses the entire spectrum of preclinical research, from initial concept validation to in-depth mechanistic studies.
Identification and Validation of Drug Targets for Psoriasis
Identifying key molecular targets is a critical first step in developing effective therapies. We utilize automated systems to rapidly assess large libraries of compounds against specific biological targets related to psoriasis. This allows for efficient identification of promising therapeutic candidates. By analyzing genomic and proteomic data, we identify crucial targets that can be modulated to achieve therapeutic effect.
Design and Synthesize of DNA-based Antipsoriatic Therapeutics
- Antisense Oligonucleotide (ASO) Development
We assist our clients in the design of ASOs that can effectively bind to and inhibit the expression of specific mRNA targets associated with psoriasis.
Service Options Descriptions Chemical Modification Applies phosphorothioate modifications and 2'-O-methyl ribonucleotide substitutions to enhance the stability and efficacy of the ASOs. Sequence Optimization Conduct thorough analyses of various sequences to identify the most effective designs for specific targets, ensuring maximal therapeutic efficiency. Quality Control To ensure the production of high-quality oligonucleotides, we utilize high-performance liquid chromatography (HPLC) and ion-exchange chromatography. - Plasmid DNA Construction
We specialize in the engineering of plasmid DNA optimized for high-level expression of therapeutic proteins.
Service Options Descriptions Promoter Selection We choose strong, tissue-specific promoters to drive gene expression in relevant cell types, maximizing therapeutic impact. Incorporation of Regulatory Elements We integrate enhancers and insulators to precisely regulate gene expression levels, ensuring optimal performance. Quality Control We conduct comprehensive characterization of plasmid constructs, including sequence verification and functional assays.
Development and Optimization of DNA Delivery Systems
Effective delivery of DNA-based therapies is crucial for achieving therapeutic efficacy.
| Service Options | Descriptions |
| Formulation Development | We assist in formulating DNA constructs with various carriers, including lipid nanoparticles and polymers, to enhance stability and cellular uptake. |
| Nanoparticle Design | Our group develops and analyzes nanoparticles specifically engineered for the effective administration of DNA treatments. This involves refining their size, charge, and surface alterations to enhance target precision and effectiveness. |
| Optimization of DNA Delivery | We evaluate various delivery methods, such as electroporation and microinjection, to facilitate the introduction of DNA into target cells. |
Preclinical Efficacy Evaluation of DNA-based Antipsoriatic Therapeutics
- In Vitro Assays: We utilize human keratinocyte and immune cell cultures to evaluate the biological activity of the DNA-based therapeutics.
- In Vivo Models: We employ relevant animal models of psoriasis to evaluate the therapeutic potential of the DNA-based therapeutics in a physiological context.
The development of DNA-based therapies presents an opportunity to address the challenges of psoriasis. Ace Therapeutics is dedicated to advancing the development of these innovative therapies by leveraging our expertise, advanced methodologies, and commitment to quality. Contact us today to learn more about our services and how we can help you achieve your research objectives.
Reference
- Korkmaz E, et al. Spherical Nucleic Acids as Emerging Topical Therapeutics: A Focus on Psoriasis. J Invest Dermatol. 2020;140(2):278-281.